Explore

Scientists Develop WHOLISTIC Method for Whole-Organism Cellular Communication Mapping

Scientists Develop WHOLISTIC Method for Whole-Organism Cellular Communication Mapping

Scientists at the Howard Hughes Medical Institute in the U.S. have developed a new imaging technique called WHOLISTIC (WHole-Organism Live-Imaging System for recording Tissue and IntraCellular activity) that allows for the observation of cellular communication across an entire living organism. This breakthrough, detailed in a study published in Nature, utilizes genetic engineering to make nearly every cell in the body express fluorescent calcium sensors. These sensors illuminate when calcium levels within cells shift, providing real-time insights into cellular activity. The technique has been successfully applied to transparent animals like larval zebrafish and Danionella cerebrum, capturing biological processes such as brainstem-controlled redistribution of body-wide blood flow. This method bridges the gap between cellular and organismal scales of biology, offering an unprecedented view of how the body functions as a whole.

New Brain Atlas Reveals Neurons Build Identity Post-Birth, Challenging Traditional Development Concepts

New Brain Atlas Reveals Neurons Build Identity Post-Birth, Challenging Traditional Development Concepts

A new study from the Stowers Institute for Medical Research, led by Assistant Investigator Neşet Özel, Ph.D., has unveiled a detailed developmental atlas of the fruit fly (Drosophila) visual system. This atlas, which mapped 232,251 individual cells across development, reveals that neurons do not simply inherit their identity from parent stem cells. Instead, their identity is actively established during a brief, critical window immediately after birth, when the regulatory landscape of their DNA undergoes dramatic remodeling. The research, published in Proceedings of the National Academy of Sciences, challenges the long-held concept that neuronal identity is a smooth continuation of a predetermined path. The study found that many enhancers associated with neuronal identity were closed in the parent stem cell and only opened after the neuron completed its final cell division. Furthermore, the research indicated that there is no single master regulator dictating identity; instead, each neuron uses its own uniq...

Good Medicine Podcast Highlights Challenges of Mouse Models in Drug Development

Good Medicine Podcast Highlights Challenges of Mouse Models in Drug Development

The Good Medicine Podcast, featuring Dr. David Bearss and Dr. Jeremiah Bearss, recently discussed a significant challenge in modern drug development: the limitations of mouse models. The podcast highlighted that despite drug development taking an average of 15 years and costing billions of dollars, most therapies that show promise in mouse models ultimately fail in human trials. Only a small percentage of therapies effective in mice succeed in people, leading to substantial impacts on timelines and costs within the pharmaceutical industry. The discussion emphasized the need for more predictive testing systems to improve pharmaceutical innovation and reduce the financial burden associated with failed drug candidates. The core issue is that animal models, particularly mice, often do not accurately predict human responses to drugs, leading to a high attrition rate in clinical development.

Johns Hopkins Researchers Develop CloudScope for Continuous Brain Activity Monitoring in Mice

Johns Hopkins Researchers Develop CloudScope for Continuous Brain Activity Monitoring in Mice

Researchers at Johns Hopkins Medicine have developed a new brain imaging approach called CloudScope, which allows for continuous monitoring of brain activity and physiological changes in freely moving mice for over 24 hours. This miniaturized, cloud-based microscope operates autonomously, providing scientists with remote access to live imaging data globally. The technology addresses a long-standing challenge in neuroscience: observing biological processes in the brain that unfold over extended periods. Using CloudScope, the team successfully captured spontaneous seizures in mice that would have been missed by conventional short-term imaging. In brain cancer studies, researchers were able to characterize individual cancer cell behavior and observe dynamic changes in the brain's microenvironment as the disease progressed. This innovation provides a more comprehensive understanding of brain disease progression compared to traditional imaging methods, which typically offer only limited observation windows.

Ainnocence Inc. Unveils AINN-P1 Protein Model Outperforming Larger AI in Drug Discovery

Ainnocence Inc. Unveils AINN-P1 Protein Model Outperforming Larger AI in Drug Discovery

Ainnocence Inc. Unveils AINN-P1 Protein Model Outperforming Larger AI in Drug Discovery

Gilead Sciences Opens New Research Center in California, Expanding Drug Discovery Capabilities

Gilead Sciences Opens New Research Center in California, Expanding Drug Discovery Capabilities

Gilead Sciences Opens New Research Center in California, Expanding Drug Discovery Capabilities

FDA Clears CU Anschutz Clinical Trial for Engineered Immune Cells Against Colorectal Cancer

FDA Clears CU Anschutz Clinical Trial for Engineered Immune Cells Against Colorectal Cancer

The U.S. Food and Drug Administration (FDA) has granted permission for a clinical trial at the University of Colorado Anschutz to test genetically engineered immune cells against advanced colorectal cancer in adults and solid cancers in pediatric patients. This experimental CAR T-cell therapy, developed by CU Anschutz researchers and manufactured at the campus's Gates Biomanufacturing Facility, is designed to target two pathways: B7-H3, a protein found on most colorectal tumors, and IL-8, which promotes tumor growth and spread. The trial aims to address the challenges of treating solid tumors, which have been more difficult to tackle with CAR T-cell therapies compared to blood cancers. The approach has shown effectiveness in animal models, and the trial is expected to begin in December.

Ainnocence Inc. Unveils AINN-P1, a Protein Foundation Model Outperforming Larger AI Models in Drug Discovery

Ainnocence Inc. Unveils AINN-P1, a Protein Foundation Model Outperforming Larger AI Models in Drug Discovery

Ainnocence Inc. Unveils AINN-P1, a Protein Foundation Model Outperforming Larger AI Models in Drug Discovery

Rakuten Medical Appoints Christophe Weber and Ken Takeshita to Board, Hassan Danesi as CMO to Accelerate U.S. Growth and Oncology Innovation

Rakuten Medical Appoints Christophe Weber and Ken Takeshita to Board, Hassan Danesi as CMO to Accelerate U.S. Growth and Oncology Innovation

Rakuten Medical Appoints Christophe Weber and Ken Takeshita to Board, Hassan Danesi as CMO to Accelerate U.S. Growth and Oncology Innovation

Autolus Therapeutics Receives FDA RMAT Designation for Obe-cel in Lupus Treatment

Autolus Therapeutics Receives FDA RMAT Designation for Obe-cel in Lupus Treatment

Autolus Therapeutics plc, a biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to obecabtagene autoleucel (obe-cel). This designation is specifically for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN). The RMAT designation is a program established under the 21st Century Cures Act, designed to expedite the development and regulatory review process for regenerative medicine therapies, including cell therapies, that are intended to treat serious or life-threatening diseases. Autolus Therapeutics is currently enrolling patients in LUMINA, a pivotal Phase 2 study for obe-cel in refractory lupus nephritis, and expects to report data in 2028. The company also submitted a data update from the Phase 1 CARLYSLE trial for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of 2026.

Matica Biotechnology and Bondwell Technologies Partner to Boost Texas Biotech Innovation

Matica Biotechnology and Bondwell Technologies Partner to Boost Texas Biotech Innovation

Matica Biotechnology and Bondwell Technologies Partner to Boost Texas Biotech Innovation

Editas Medicine Prepares for First Human Trial of CRISPR Cholesterol Therapy EDIT-401

Editas Medicine Prepares for First Human Trial of CRISPR Cholesterol Therapy EDIT-401

Editas Medicine is advancing towards a first-in-human study for EDIT-401, an in vivo CRISPR-edited medicine designed to reduce LDL cholesterol in patients with heterozygous familial hypercholesterolemia. According to CEO Gilmore O’Neill, the company is focused on in vivo CRISPR-edited medicines that offer differentiated efficacy and utilize gene-editing capabilities. EDIT-401 aims to increase the production of LDL receptors in liver cells, thereby enhancing the removal of LDL cholesterol from the bloodstream. Preclinical findings in non-human primates showed a mean reduction of 90% in LDL cholesterol, lipoprotein(a), and apolipoprotein B. The treatment is designed as a single intravenous infusion. Editas Medicine has submitted documentation to human research ethics committees in Australia and plans to dose the first patients this year. The Phase 1 trial will involve serial dose-escalation cohorts and an expansion into a broader patient population. The company anticipates sharing safety data in the first qu...